{"id":"mefuparib","rwe":[{"pmid":"40957266","year":"2025","title":"Discovery of a novel benzofuran-7-carboxamide-based PARP1/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance.","finding":"","journal":"European journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"39637187","year":"2024","title":"Utility of quantitative whole-body autoradiography (QWBA) and oxidative combustion (OC) analysis in the assessment of tissue distribution of [14C]Mefuparib (CVL218) in SD and LE rats.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"36283983","year":"2022","title":"Absorption, distribution, metabolism, and excretion of [(14)C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats.","finding":"","journal":"Cancer chemotherapy and pharmacology","studyType":"Clinical Study"},{"pmid":"35078755","year":"2022","title":"Covid-19 and Artificial Intelligence: Genome sequencing, drug development and vaccine discovery.","finding":"","journal":"Journal of infection and public health","studyType":"Clinical Study"},{"pmid":"33151287","year":"2021","title":"DrugCentral 2021 supports drug discovery and repositioning.","finding":"","journal":"Nucleic acids research","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Poly [ADP-ribose] polymerase 2","category":"target"},{"label":"PARP2","category":"gene"},{"label":"PARP1","category":"gene"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["mefuparib","mefuparib hydrochloride","CVL218"],"offLabel":[],"synonyms":["mefuparib","mefuparib hydrochloride","CVL218"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Poly [ADP-ribose] polymerase 1, Poly [ADP-ribose] polymerase 2","targets":[{"gene":"PARP2","source":"DrugCentral","target":"Poly [ADP-ribose] polymerase 2","protein":"Poly [ADP-ribose] polymerase 2"},{"gene":"PARP1","source":"DrugCentral","target":"Poly [ADP-ribose] polymerase 1","protein":"Poly [ADP-ribose] polymerase 1"}],"modality":"Small Molecule","explanation":"Imagine your DNA is a long, fragile thread. PARP2 helps repair breaks in this thread by adding special molecules to fix the damage. Mefuparib blocks this repair process, which can be beneficial in treating cancer cells that rely heavily on PARP2 for survival.","oneSentence":"Mefuparib works by inhibiting the activity of PARP2, a protein that helps repair damaged DNA.","technicalDetail":"Mefuparib binds to the PARP2 active site, preventing the enzyme from catalyzing the transfer of ADP-ribose units to target proteins, thereby inhibiting PARP2-mediated DNA repair and potentially inducing DNA damage in cancer cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5378","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=mefuparib","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:33:19.490940","biosimilars":[],"competitors":[{"drugName":"niraparib","drugSlug":"niraparib","fdaApproval":"2017-03-27","patentExpiry":"Mar 27, 2038","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"olaparib","drugSlug":"olaparib","fdaApproval":"2014-12-19","patentExpiry":"Sep 8, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"rucaparib","drugSlug":"rucaparib","fdaApproval":"2016-12-19","patentExpiry":"Feb 10, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"talazoparib tosylate","drugSlug":"talazoparib-tosylate","fdaApproval":"2018-10-16","patentExpiry":"Oct 20, 2031","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"mefuparib","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"niraparib","brandName":"niraparib","genericName":"niraparib","approvalYear":"2017","relationship":"same-target"},{"drugId":"olaparib","brandName":"olaparib","genericName":"olaparib","approvalYear":"2014","relationship":"same-target"},{"drugId":"rucaparib","brandName":"rucaparib","genericName":"rucaparib","approvalYear":"2016","relationship":"same-target"},{"drugId":"talazoparib-tosylate","brandName":"talazoparib tosylate","genericName":"talazoparib tosylate","approvalYear":"2018","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"9NN2OZ1YX4","CHEBI":"CHEBI:167899","UMLSCUI":"C4705074","PUBCHEM_CID":"71488522","SECONDARY_CAS_RN":"1449746-00-2","MESH_SUPPLEMENTAL_RECORD_UI":"C000626298"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec 15","pmid":"40957266","title":"Discovery of a novel benzofuran-7-carboxamide-based PARP1/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance.","journal":"European journal of medicinal chemistry"},{"date":"2024","pmid":"39637187","title":"Utility of quantitative whole-body autoradiography (QWBA) and oxidative combustion (OC) analysis in the assessment of tissue distribution of [14C]Mefuparib (CVL218) in SD and LE rats.","journal":"PloS one"},{"date":"2022 Dec","pmid":"36283983","title":"Absorption, distribution, metabolism, and excretion of [(14)C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats.","journal":"Cancer chemotherapy and pharmacology"},{"date":"2022 Feb","pmid":"35078755","title":"Covid-19 and Artificial Intelligence: Genome sequencing, drug development and vaccine discovery.","journal":"Journal of infection and public health"},{"date":"2021 Jan 8","pmid":"33151287","title":"DrugCentral 2021 supports drug discovery and repositioning.","journal":"Nucleic acids research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"mefuparib","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Mefuparib is a small molecule modality targeting Poly [ADP-ribose] polymerase 2 (PARP2), a protein involved in DNA repair. Its mechanism of action is not classified into a specific drug class. Mefuparib's commercial status and approved indications are currently unknown. Further research is needed to determine its efficacy and safety profile. As a PARP inhibitor, mefuparib may have potential in treating certain types of cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}